Thierry Henaff - Arkema S Insider

ARKAF -- USA Stock  

USD 118.55  0.000003  0.00%

Chairman of the Board, CEO, Member of the Executive Committee

Mr. Thierry Le Henaff was the Chairman of the Board, Chief Executive Officer and Member of the Executive Committee of Arkema SA since March 6, 2006. He holds a degree from Ecole Polytechnique and Ecole Nationale des Ponts et Chaussees and a Masters in Industrial Management from Stanford University. After he began his career at Peat Marwick Consultants he moved to Bostik, the adhesives division at Total, in 1992. He held several positions of operational responsibility in France and abroad. In July 2001, he became Chief Executive Officer of Bostik Findely, a new entity created through the merger of the adhesives activities of Total and Elf Atochem. On January 1, 2003, he joined the Management Committee of Atofina, within which he supervised three business units and three functional divisions. He was Chairman and Managing Director of Arkema France, Managing Director of Grande Paroisse, Director of Cray Valley, Bostik Findley S.A. and Cerexagri Inc. He has served as Chairman of the Board of Directors of Arkema France since April 18, 2006, in which he was Chairman and Chief Executive Officer since 2004.
Age: 53  Chairman Since 2006      
33 1 49 00 80 80

Management Efficiency

The company has return on total asset (ROA) of 6.1 % which means that it generated profit of $6.1 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 14.04 % meaning that it generated $14.04 on every $100 dollars invested by stockholders.
The company has accumulated 2.91 B in total debt with debt to equity ratio (D/E) of 54.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Arkema S A has Current Ratio of 2.3 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 2 records


Amir ElsteinTeva Pharmaceutical Industries
Ramesh MisraSJVN Limited

Entity Summary

Its High Performance Materials segment offers adhesives and sealants for industry, hygiene, construction, and consumer products and specialty polyamides for automotive, aerospace, aeronautics, oil and gas, electronics, and consumer goods, as well as polyvinylidene fluoride for chemical engineering, paints and anti-corrosive coatings, oil and gas extraction, photovoltaic panels, lithium-ion batteries, and water treatment membranes. The company was incorporated in 2003 and is headquartered in Colombes, France. Arkema S is traded on OTC Market in USA.Arkema S A (ARKAF) is traded on OTC Market in USA. It is located in 420 rue d'Estienne d'Orves and employs 20,000 people.

Arkema S A Leadership Team

Patrice Breant, Director, Ph.D
Vincent Legros, President
Victoire Margerie, Director, Ph.D
Jerome Gandon, Executive
Sophie Fouillat, VP
Marc Pandraud, Director
Helene MoreauLeroy, Director
Claire Pedini, Director
Marc Schuller, EVP
Bernard Kasriel, Director
Thierry Morin, Director
Philippe Vassor, Director
Bernard Boyer, President
Luc BenoitCattin, President
Nathalie Muracciole, Director
Thierry Lemonnier, CFO
Michel Delaborde, EVP
Laurent Mignon, Director
Isabelle BocconGibod, Director
Bernard Pinatel, President, MBA
Thierry Henaff, Chairman
Francois Enaud, Director
MarieJose Donsion, Director
Christophe Andre, President, MBA

Stock Performance Indicators

Did you try this?

Run Price Exposure Probability Now

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Price Exposure Probability

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Arkema S and SJVN Limited. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.